Document Detail

Calming the plaque to delay intervention for 24 hours in acute coronary syndromes.
MedLine Citation:
PMID:  11206014     Owner:  NLM     Status:  MEDLINE    
One approach to management of patients with acute coronary syndromes involves use of pharmacologic therapy to passivate plaque for at least 24 hours before interventional procedures are undertaken. This approach is supported by the view that whatever subsequent treatment the patient receives will less likely be complicated. An important factor in revolutionizing treatment for acute coronary syndromes in recent years has been the introduction of potent new antithrombotic and antiplatelet pharmacologic therapies such as low-molecular-weight heparins and glycoprotein IIb/IIIa inhibitors. Incorporation of these newer agents into clinical practice, along with a better understanding of the pathophysiology underlying acute coronary syndromes, has contributed greatly to improved outcomes in these patients. Although the optimal methods for integrating the newer therapies remains to be determined, thus far, they have been shown to lower the risk of acute complications, as well as improve long-term results.
M Cohen
Related Documents :
19814664 - Anticoagulation for heart failure: selecting the best therapy.
7850674 - What do we really know about secondary prevention after myocardial infarction?
10731264 - Successful non-operative management of right coronary artery perforation during percuta...
14642154 - Advances in antithrombin therapy for st-elevation myocardial infarction.
3155304 - Clinical electrophysiologic effects of flecainide acetate.
2015774 - Management of valvular heart disease: an illustrative cases approach.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  The American journal of cardiology     Volume:  86     ISSN:  0002-9149     ISO Abbreviation:  Am. J. Cardiol.     Publication Date:  2000 Dec 
Date Detail:
Created Date:  2001-02-02     Completed Date:  2001-02-22     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  0207277     Medline TA:  Am J Cardiol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  18M-26M     Citation Subset:  AIM; IM    
MCP Hahnemann University School of Medicine, Philadelphia, Pennsylvania 19102, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Angina, Unstable / drug therapy*,  physiopathology
Anticoagulants / therapeutic use
Heparin, Low-Molecular-Weight / therapeutic use
Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use
Myocardial Infarction / drug therapy*,  physiopathology
Platelet Glycoprotein GPIIb-IIIa Complex / antagonists & inhibitors
Randomized Controlled Trials as Topic
Reg. No./Substance:
0/Anticoagulants; 0/Heparin, Low-Molecular-Weight; 0/Hydroxymethylglutaryl-CoA Reductase Inhibitors; 0/Platelet Glycoprotein GPIIb-IIIa Complex

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Therapeutic adjuncts for immediate transfer to the catheterization laboratory in patients with acute...
Next Document:  An ischemia-guided approach for risk stratification in patients with acute coronary syndromes.